| Trial registration number
|
NCT04753619 |
Full text link
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT04753619
|
First author
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Faiq I. Gorial, Professor
|
Contact
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
faiqig@yahoo.com
|
Registration date
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
2021-02-15
|
Recruitment status
Last imported at : June 5, 2023, 8 a.m.
Source : ClinicalTrials.gov
|
Unknown
|
Study design
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
RCT
|
Allocation
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Randomized
|
Design
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Parallel
|
Masking
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Open label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
single-center
|
Study aim
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Treatment
|
Inclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
patients with age above 18 years and of any gender.
definite diagnosis of covid-19 according to the who classification criteria ( 18).
patients symptomatic for no more than three days for mild-moderate cases, no more than two days after being severe cases, and no more than one day after being critical cases.
understands and agrees to comply with planned study procedures.
|
Exclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m.
Source : ClinicalTrials.gov
|
patients refuse to enrol in the study
patients with hypersensitivity or severe adverse effects to niclosamide
renal impairment
hepatic impairment
pregnancy or a desire to become pregnant
breast feeding
|
Number of arms
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
2
|
Funding
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
University of Baghdad
|
Inclusion age min
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
18
|
Inclusion age max
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
100
|
Countries
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Iraq
|
Type of patients
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
No restriction on type of patients
|
Severity scale
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
0: No restriction on type of patients
|
Total sample size
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
150
|
primary outcome
Last imported at : Feb. 19, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Percentage of Cure of the patient;Time to recovery
|
Notes
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m.
Source : ClinicalTrials.gov
|
Phase 2
|
Arms
Last imported at : Feb. 17, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "", "treatment_id": 883, "treatment_name": "Niclosamide", "treatment_type": "Antiparasitics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
|